Table 7.
Anti-JCV AI categories and patient’s treatment.
| n (%) | Naïve | IS | IM | KW-H | CLA | CTX | Mx | KW-H | IFN | GA | DMF | FGL | NTZ | KW-H |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JCV AI ≤ 0.2 | 142 (21.4) | 30 (14.4) | 119 (22.4) | KW-H p = 0.0007 post hoc IS/IM p = 0.0009 IS/Naïve p = 0.01 IM/Naïve p > 0.05 |
6 (14.6) | 9 (17.3) | 15 (13.0) | KW-H p > 0.05 | 73 (19.9) | 16 (18.8) | 8 (36.4) | 5 (15.2) | 17 (68.0) | KW-H p < 0.00001 post hoc GA/NTZ p = 0.00006 IFN/NTZ p = 0.0005 S1P/NTZ p = 0.00001 Other p > 0.05 |
| 0.2 < JCV AI ≤ 0.4 | 99 (14.9) | 23 (11.1) | 90 (16.9) | 5 (12.2) | 4 (7.7) | 14 (12.2) | 66 (18.0) | 13 (15.3) | 4 (18.2) | 2 (6.1) | 5 (20.0) | |||
| 0.4 < JCV AI ≤ 0.9 | 87 (13.1) | 25 (12.0) | 76 (14.3) | 8 (19.5) | 6 (11.5) | 11 (9.6) | 60 (16.3) | 11 (12.9) | 3 (13.6) | 2 (6.1) | – | |||
| 0.9 < JCV AI ≤ 1.5 | 63 (9.5) | 23 (11.1) | 43 (8.1) | 3 (7.3) | 12 (23.1) | 8 (7.0) | 27 (7.4) | 9 (10.6) | 1 (4.5) | 6 (18.2) | – | |||
| JCV AI > 1.5 | 274 (41.2) | 107 (51.4) | 204 (38.3) | 19 (46.3) | 21 (40.4) | 67 (58.3) | 141 (38.4) | 36 (42.4) | 6 (27.3) | 18 (54.5) | 3 (12.0) |
IS—classical immunosuppressants, IM—immunomodulatory drugs and selective immunosuppressants, IFN—interferon, GA—glatiramer acetate, DMF—dimethyl fumarate, FGL—fingolimod, NTZ—natalizumab, Mx—mitoxantrone, CTX—cyclophosphamide, CLA—cladribine in vials for subcutaneous administration, and JCV AI—anti-JCV Ab index.